Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Hideo, Yagi"'
Autor:
Yutaka Shimazu, Junya Kanda, Satoru Kosugi, Tomoki Ito, Hitomi Kaneko, Kazunori Imada, Yuji Shimura, Shin-ichi Fuchida, Kentaro Fukushima, Hirokazu Tanaka, Satoshi Yoshihara, Kensuke Ohta, Nobuhiko Uoshima, Hideo Yagi, Hirohiko Shibayama, Ryosuke Yamamura, Yasuhiro Tanaka, Hitoji Uchiyama, Yoshiyuki Onda, Yoko Adachi, Hitoshi Hanamoto, Ryoichi Takahashi, Mitsuhiro Matsuda, Takashi Miyoshi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Novel therapeutic drugs have dramatically improved the overall survival of patients with multiple myeloma. We sought to identify the characteristics of patients likely to exhibit a durable response to one such drug, elotuzumab, by analyzing
Externí odkaz:
https://doaj.org/article/f9f360c7a7b8496ea74ce32ada6c5c4d
Autor:
Aya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, Ryosuke Yamamura, Satoshi Yoshioka, Kazunori Imada, Yuji Shimura, Masaaki Hotta, Toshimitsu Matsui, Satoru Kosugi, Hitoshi Hanamoto, Hitoji Uchiyama, Satoshi Yoshihara, Shin-ichi Fuchida, Yoshiyuki Onda, Yasuhiro Tanaka, Kensuke Ohta, Mitsuhiro Matsuda, Junya Kanda, Adachi Yoko, Miki Kiyota, Eri Kawata, Ryoichi Takahashi, Kentaro Fukushima, Hirokazu Tanaka, Hideo Yagi, Teruhito Takakuwa, Naoki Hosen, Tomoki Ito, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Masayuki Hino
Publikováno v:
Leukemia Research Reports, Vol 20, Iss , Pp 100395- (2023)
To evaluate the specific prognostic value of CAs, we conducted an analysis of 923 symptomatic multiple myeloma patients. Among this cohort, 480 patients had complete data set of high-risk CAs by interphase fluorescent in situ hybridization at diagnos
Externí odkaz:
https://doaj.org/article/82b016d7b6d64623a8db970348a6c492
Autor:
Yutaka Shimazu, Junya Kanda, Hitomi Kaneko, Kazunori Imada, Ryosuke Yamamura, Satoru Kosugi, Yuji Shimura, Tomoki Ito, Shin-ichi Fuchida, Hitoji Uchiyama, Kentaro Fukushima, Satoshi Yoshihara, Hitoshi Hanamoto, Hirokazu Tanaka, Nobuhiko Uoshima, Kensuke Ohta, Hideo Yagi, Hirohiko Shibayama, Yoshiyuki Onda, Yasuhiro Tanaka, Yoko Adachi, Mitsuhiro Matsuda, Masato Iida, Takashi Miyoshi, Toshimitsu Matsui, Ryoichi Takahashi, Teruhito Takakuwa, Masayuki Hino, Naoki Hosen, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Daratumumab is one of the most widely used treatments for relapsed/refractory multiple myeloma (MM) patients. However, not all patients achieve a lasting therapeutic response with daratumumab. Objectives: We hypothesized that a durable re
Externí odkaz:
https://doaj.org/article/de0e47159d65497ba083e4d809b5a35a
Autor:
Aya Nakaya, Hirohiko Shibayama, Eiji Nakatani, Yuji Shimura, Satoru Kosugi, Hirokazu Tanaka, Shin‐Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Hitomi Kaneko, Kazunori Imada, Kensuke Ohta, Tomoki Ito, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori‐Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 765-773 (2021)
Abstract A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high‐dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4‐year overall survival (OS) of patients with maintenance (n = 82
Externí odkaz:
https://doaj.org/article/fca8d9086da64417a2e3ae2412495e6f
Autor:
Yoshiyuki Onda, Junya Kanda, Hitomi Kaneko, Yuji Shimura, Shin-ichi Fuchida, Aya Nakaya, Tomoki Itou, Ryosuke Yamamura, Hirokazu Tanaka, Hirohiko Shibayama, Yutaka Shimazu, Hitoji Uchiyama, Satoshi Yoshihara, Yoko Adachi, Mitsuhiro Matsuda, Hitoshi Hanamoto, Nobuhiko Uoshima, Satoru Kosugi, Kensuke Ohta, Hideo Yagi, Yuzuru Kanakura, Itaru Matsumura, Masayuki Hino, Shosaku Nomura, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: Little is known about the real-world survival benefits and safety profiles of carfilzomib–lenalidomide–dexamethasone (KRd) and carfilzomib–dexamethasone (Kd). Methods: We performed a retrospective analysis to evaluate their efficacy
Externí odkaz:
https://doaj.org/article/c8a169335f1a487791719eaf9c1c6082
Autor:
Hidekazu Azumi, Masayuki Kubo, Atsushi Otani, Shinichi Ochi, Shinya Kobayashi, Yasumasa Miyataka, Fumihiko Nakamura, Hideo Yagi
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 14, p2069-2076, 8p
Autor:
Yosuke Aihara, Kei Moriya, Naotaka Shimozato, Shinsaku Nagamatsu, Shinya Kobayashi, Masakazu Uejima, Hideki Matsuo, Eiwa Ishida, Hideo Yagi, Toshiya Nakatani, Hitoshi Yoshiji, Eiryo Kikuchi
Publikováno v:
BMC Gastroenterology, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Chronic active Epstein–Barr virus infection (CAEBV) is defined as Epstein–Barr virus (EBV)-positive T/NK cell-related neoplasia, and its major clinical symptom is systemic inflammation presenting as infectious mononucleocytosi
Externí odkaz:
https://doaj.org/article/46a637fb8c424562b5c21260fafc43fe
Publikováno v:
Haematologica, Vol 105, Iss 11 (2019)
von Willebrand factor (VWF) is a blood glycoprotein that plays an important role in platelet thrombus formation through interaction between its A1 domain and platelet glycoprotein Ib. ARC1779, an aptamer to the VWF A1 domain, was evaluated in a clini
Externí odkaz:
https://doaj.org/article/42d77f15b79c4ab38ec01f458085285c
Autor:
Aya Nakaya, Hideo Yagi, Hitomi Kaneko, Satoru Kosugi, Toru Kida, Yoko Adachi, Hirohiko Shibayama, Takae Kohara, Yuri Kamitsuji, Shin-ichi Fuchida, Nobuhiko Uoshima, Eri Kawata, Hitoji Uchiyama, Yuji Shimura, Takayuki Takahashi, Fumiaki Urase, Kensuke Ohta, Tsuneyoshi Hamada, Kazue Miyamoto, Masayuki Kobayashi, Maki Shindo, Hirokazu Tanaka, Chihiro Shimazaki, Masayuki Hino, Junya Kuroda, Yuzuru Kanakura, Akifumi Takaoari-Kondo, Shosaku Nomura, Itaru Matsumura
Publikováno v:
Leukemia Research Reports, Vol 10, Iss , Pp 7-10 (2018)
We retrospectively analyzed twenty-six patients with primary plasma cell leukemia (pPCL) registered from May 2005 until April 2015 by the Kansai Myeloma Forum. Twenty patients received novel agents (bortezomib or lenalidomide), and their median survi
Externí odkaz:
https://doaj.org/article/60725e003e734cd185128c760bbe013a
Autor:
Yoko Yoshida, Masanori Matsumoto, Hideo Yagi, Ayami Isonishi, Kazuya Sakai, Masaki Hayakawa, Yuji Hori, Toshiyuki Sado, Hiroshi Kobayashi, Yoshihiro Fujimura
Publikováno v:
Blood Advances, Vol 1, Iss 20, Pp 1628-1631 (2017)
Externí odkaz:
https://doaj.org/article/482cba960240427baa01ce9299307dd1